Prevalence, predictors, and clinical consequences of medical adherence in IBD: How to improve it?

World Journal of Gastroenterology

Volumn 15, Issue 34, 2009, Pages 4234-4239

  Lakatos, Peter Laszlo ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

5 aminosalicylate; Adherence; Azathioprine; Compliance; Crohn's disease; Inflammatory bowel disease; Mesalazine; Therapy; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; BALSALAZIDE; ENEMA; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; SALAZOSULFAPYRIDINE; STEROID;

AGE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COLONOSCOPY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DOCTOR PATIENT RELATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; EDUCATIONAL STATUS; EMPLOYMENT STATUS; ENTERITIS; HUMAN; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PHENOTYPE; PREDICTION; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SELF REPORT; SEX DIFFERENCE; ULCERATIVE COLITIS; EDITORIAL; EPIDEMIOLOGY; RISK FACTOR; STATISTICS;

CAUSALITY; HUMANS; INFLAMMATORY BOWEL DISEASES; PATIENT COMPLIANCE; RISK FACTORS;

EID: 70349571888     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.4234     Document Type: Review

References (36)

1. Lakatos PL, Fischer S, Lakatos L, Gal I, Papp J. Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll" ? World J Gastroenterol 2006; 12: 1829-1841
2. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006; 12: 6102-6108
3. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-2933
4. Robinson A. Review article: improving adherence to medication in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27 Suppl 1: 9-14
5. Cervený P, Bortlík M, Kubena A, Vlcek J, Lakatos PL, Lukás M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007; 13: 1244-1249 (Pubitemid 47597771)
6. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999; 47: 555-567 (Pubitemid 30029305)
7. Horne R, Parham R, Driscoll R, Robinson A. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 837-844
8. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 521-530
9. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 1471-1478 (Pubitemid 39265268)
10. Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, Dobkin PL. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1535-1544 (Pubitemid 36875345)
11. Hommel KA, Davis CM, Baldassano RN. Objective versus subjective assessment of oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 589-593
12. Belaiche J, Desager JP, Horsmans Y, Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001; 36: 71-76 (Pubitemid 32147184)
13. Rubin G, Hungin AP, Chinn D, Dwarakanath AD, Green L, Bates J. Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Aliment Pharmacol Ther 2002; 16: 1889-1893 (Pubitemid 35253004)
14. Bernal I, Domènech E, Garcia-Planella E, Marín L, Mañosa M, Navarro M, Cabré E, Gassull MA. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006; 51: 2165-2169
15. Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. BMJ 1993; 307: 846-848
16. Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, McPhail C, Deering K, Bernstein CN. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007; 102: 1417-1426 (Pubitemid 46976288)
17. Mackner LM, Crandall WV. Oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 1006-1012 (Pubitemid 41580015)
18. Oliva-Hemker MM, Abadom V, Cuffari C, Thompson RE. Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease. J Pediatr Gastroenterol Nutr 2007; 44: 180-184 (Pubitemid 46175069)
19. Bokemeyer B, Teml A, Roggel C, Hartmann P, Fischer C, Schaeffeler E, Schwab M. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther 2007; 26: 217-225 (Pubitemid 46985496)
20. Mantzaris GJ, Roussos A, Kalantzis C, Koilakou S, Raptis N, Kalantzis N. How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission? Inflamm Bowel Dis 2007; 13: 446-450 (Pubitemid 46668250)
21. Shale MJ, Riley SA. Studies of compliance with delayedrelease mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191-198 (Pubitemid 36951655)
22. D'Incà R, Bertomoro P, Mazzocco K, Vettorato MG, Rumiati R, Sturniolo GC. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther 2008; 27: 166-172 (Pubitemid 350256604)
23. Lakatos PL, David G, Gemela O, Palatka K, Kristof T, Nagy F, Salamon A, Lakatos L. Adherence to therapy and use of complementary and alternative medicine in patients with inflammatory bowel diseases [abstract]. Gastroenterology 2009; 136 Suppl 1: S1162
24. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39-43 (Pubitemid 36126514)
25. Kane S, Hanauer SB. National adherence rates with IBD therapy: PO vs PR [abstract]. Am J Gastroenterol 2001; 96: S296
26. Greenley RN, Stephens M, Doughty A, Raboin T, Kugathasan S. Barriers to adherence among adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2009; Epub ahead of print
27. Magowan S, Kane S, Lange JL. 5-ASA prescription refill rates for ulcerative colitis are independent of formulation and dosing regimens [abstract]. Am J Gastroenterol 2006; 101: S447
28. Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veerman H. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 762-769
29. Kruis W, Kiudelis G, Rácz I, Gorelov IA, Pokrotnieks J, Horynski M, Batovsky M, Kykal J, Boehm S, Greinwald R, Mueller R. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009; 58: 233-240
30. Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007; 26: 205-215 (Pubitemid 46985493)
31. López San Román A, Bermejo F, Carrera E, Pérez-Abad M, Boixeda D. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig 2005; 97: 249-257 (Pubitemid 40755660)
32. Rost K, Carter W, Inui T. Introduction of information during the initial medical visit: consequences for patient follow-through with physician recommendations for medication. Soc Sci Med 1989; 28: 315-321 (Pubitemid 19053141)
33. Krueger KP, Felkey BG, Berger BA. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. J Am Pharm Assoc (2003) 2003; 43: 668-678; quiz 678-679
34. Waters BM, Jensen L, Fedorak RN. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol 2005; 19: 235-244
35. Kennedy AP, Nelson E, Reeves D, Richardson G, Roberts C, Robinson A, Rogers AE, Sculpher M, Thompson DG. A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease. Gut 2004; 53: 1639-1645 (Pubitemid 39434108)
36. Elkjaer M, Burisch J, Avnstrøm S, Lynge E, Munkholm P. Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. Eur J Gastroenterol Hepatol 2009; Epub ahead of print